Natural (and Unnatural) Small Molecules as Pharmacological Chaperones and Inhibitors in Cancer.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Handbook of Experimental Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1007/164_2017_55PMID 28993836
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protein misfolding diseases: Prospects of pharmacological treatment

  2018cited by this paper
• Retraction: Disruption of the NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Gene in Mice Causes Myelogenous Hyperplasia.

  2018cited by this paper
• Recognition of Client Proteins by the Proteasome.

  2017cited by this paper
• Inhibition of leukotriene B4 receptor 1 attenuates lipopolysaccharide-induced cardiac dysfunction: role of AMPK-regulated mitochondrial function

  2017cited by this paper
• The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.

  2017cited by this paper
• Enhanced vulnerability of human proteins towards disease-associated inactivation through divergent evolution

  2017cited by this paper
• Cotranslational folding of spectrin domains via partially structured states

  2017cited by this paper
• Proteasomal and Autophagic Degradation Systems.

  2017cited by this paper
• Dicoumarol: A Drug which Hits at Least Two Very Different Targets in Vitamin K Metabolism.

  2017cited by this paper
• Cosolutes, Crowding, and Protein Folding Kinetics.

  2017cited by this paper
• New somatic BRAF splicing mutation in Langerhans cell histiocytosis

  2017cited by this paper
• Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients

  2017cited by this paper
• MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.

  2017cited by this paper
• Site-to-site interdomain communication may mediate different loss-of-function mechanisms in a cancer-associated NQO1 polymorphism

  2017cited by this paper
• Catalytic competence, structure and stability of the cancer-associated R139W variant of the human NAD(P)H: quinone oxidoreductase 1 (NQO1)

  2017cited by this paper
• De novo mutational profile in RB1 clarified using a mutation rate modeling algorithm

  2017cited by this paper
• Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?

  2016cited by this paper
• Conformational dynamics is key to understanding loss-of-function of NQO1 cancer-associated polymorphisms and its correction by pharmacological ligands

  2016cited by this paper
• Recognition of enzymes lacking bound cofactor by protein quality control

  2016cited by this paper
• Macromolecular Crowding In Vitro, In Vivo, and In Between.

  2016cited by this paper
• Therapeutic Approaches Using Riboflavin in Mitochondrial Energy Metabolism Disorders.

  2016cited by this paper
• Natural Small Molecules as Stabilizers and Activators of Cancer-Associated NQO1 Polymorphisms.

  2016cited by this paper
• Harnessing Fluorine–Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs

  2016cited by this paper
• Trigger Factor Reduces the Force Exerted on the Nascent Chain by a Cotranslationally Folding Protein.

  2016cited by this paper
• 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells

  2016cited by this paper
• The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches.

  2016cited by this paper
• Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity

  2016cited by this paper
• TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data

  2016cited by this paper
• Globular Protein Folding In Vitro and In Vivo.

  2016cited by this paper
• An in silico algorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein.

  2016cited by this paper
• Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm

  2016cited by this paper
• Tripartite degrons confer diversity and specificity on regulated protein degradation in the ubiquitin-proteasome system

  2016cited by this paper
• The yin–yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF

  2016cited by this paper
• A child with Li–Fraumeni syndrome: Modes to inactivate the second allele of TP53 in three different malignancies

  2015cited by this paper
• The Chaperoning Activity of Amino-oxyacetic Acid on Folding-Defective Variants of Human Alanine:Glyoxylate Aminotransferase Causing Primary Hyperoxaluria Type I.

  2015cited by this paper
• A bipartite interaction between Hsp70 and CHIP regulates ubiquitination of chaperoned client proteins.

  2015cited by this paper
• The distribution of BRAF gene fusions in solid tumors and response to targeted therapy

  2015cited by this paper
• 2015 Clinical trials update in sickle cell anemia

  2015cited by this paper
• Interactive Effect of Smoking and NQO1 Haplotypes on Lung Cancer Risk

  2015cited by this paper
• Comprehensive genomic profiles of small cell lung cancer

  2015cited by this paper
• Structure of full‐length p53 tumor suppressor probed by chemical cross‐linking and mass spectrometry

  2015cited by this paper
• Collapse of the native structure caused by a single amino acid exchange in human NAD(P)H:quinone oxidoreductase

  2014cited by this paper
• Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators

  2014cited by this paper
• The metastability of human UDP-galactose 4'-epimerase (GALE) is increased by variants associated with type III galactosemia but decreased by substrate and cofactor binding.

  2014cited by this paper
• The Mdm Network and Its Regulation of p53 Activities: A Rheostat of Cancer Risk

  2014cited by this paper
• FAD binding overcomes defects in activity and stability displayed by cancer-associated variants of human NQO1.

  2014cited by this paper
• The TP53 Gene Network in a Postgenomic Era

  2014cited by this paper
• Mutant TP53 Posttranslational Modifications: Challenges and Opportunities

  2014cited by this paper
• Chaperoning Proteins for Destruction: Diverse Roles of Hsp70 Chaperones and their Co-Chaperones in Targeting Misfolded Proteins to the Proteasome

  2014cited by this paper
• TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade

  2014cited by this paper
• Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

  2014cited by this paper
• Paradigms of protein degradation by the proteasome.

  2014cited by this paper
• Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein

  2014cited by this paper
• Mitomycinoid alkaloids: mechanism of action, biosynthesis, total syntheses, and synthetic approaches.

  2013cited by this paper
• Folding the proteome.

  2013cited by this paper
• Assessment of the contribution of NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) to the reduction of vitamin K in wild-type and NQO1-deficient mice.

  2013cited by this paper
• The DREAM complex: master coordinator of cell cycle-dependent gene expression

  2013cited by this paper
• Protein homeostasis disorders of key enzymes of amino acids metabolism: mutation-induced protein kinetic destabilization and new therapeutic strategies

  2013cited by this paper
• Small molecule induced reactivation of mutant p53 in cancer cells

  2013cited by this paper
• Folding of a Cyclin Box

  2013cited by this paper
• Molecular mechanisms underlying RB protein function

  2013cited by this paper
• The stability of 2-state, 3-state and more-state proteins from simple spectroscopic techniques... plus the structure of the equilibrium intermediates at the same time.

  2013cited by this paper
• Protein Stability, Folding and Misfolding in Human PGK1 Deficiency

  2013cited by this paper
• The human flavoproteome

  2013cited by this paper
• Molecular chaperone functions in protein folding and proteostasis.

  2013cited by this paper
• Li-Fraumeni syndrome

  2013cited by this paper
• Mutational landscape and significance across 12 major cancer types

  2013cited by this paper
• The NQO1 polymorphism C609T (Pro187Ser) and cancer susceptibility: a comprehensive meta-analysis

  2013cited by this paper
• A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells

  2013cited by this paper
• Mutant p53: one name, many proteins.

  2012cited by this paper
• SNP array profiling of childhood adrenocortical tumors reveals distinct pathways of tumorigenesis and highlights candidate driver genes.

  2012cited by this paper
• A mutually inhibitory feedback loop between the 20S proteasome and its regulator, NQO1.

  2012cited by this paper
• Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53

  2012cited by this paper
• Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade

  2012cited by this paper
• Allele-specific p53 mutant reactivation.

  2012cited by this paper
• Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis.

  2011cited by this paper
• TP53 mutations in human cancer: database reassessment and prospects for the next decade.

  2011cited by this paper
• Li-fraumeni syndrome.

  2011cited by this paper
• BRAF mutations in hairy-cell leukemia.

  2011cited by this paper
• Inhibitors of NQO1: identification of compounds more potent than dicoumarol without associated off-target effects.

  2011cited by this paper
• E3 Ligase STUB1/CHIP Regulates NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Accumulation in Aged Brain, a Process Impaired in Certain Alzheimer Disease Patients*

  2011cited by this paper
• Protein kinetic stability.

  2010cited by this paper
• Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding

  2010cited by this paper
• NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector.

  2010cited by this paper
• Pharmacological inhibitors of NAD(P)H quinone oxidoreductase, NQO1: structure/activity relationships and functional activity in tumour cells.

  2010cited by this paper
• Unfoldomics of human diseases: linking protein intrinsic disorder with diseases

  2009cited by this paper
• Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: Molecular diversity and associated phenotypic spectrum

  2009cited by this paper
• When mutants gain new powers: news from the mutant p53 field

  2009cited by this paper
• Effects of Stability on the Biological Function of p53*

  2009cited by this paper
• Stability and structural recovery of the tetramerization domain of p53-R337H mutant induced by a designed templating ligand

  2008cited by this paper
• Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

  2008cited by this paper
• Patterns of missplicing caused by RB1 gene mutations in patients with retinoblastoma and association with phenotypic expression

  2008cited by this paper
• Combining experiment and simulation in protein folding: closing the gap for small model systems.

  2008cited by this paper
• Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria.

  2008cited by this paper
• MDM2 regulates dihydrofolate reductase activity through monoubiquitination.

  2008cited by this paper
• Flexible nets: disorder and induced fit in the associations of p53 and 14-3-3 with their partners

  2008cited by this paper
• Isotope labeling studies on the formation of 5-(hydroxymethyl)-2-furaldehyde (HMF) from sucrose by pyrolysis-GC/MS.

  2008cited by this paper
• Intrinsically disordered proteins in human diseases: introducing the D2 concept.

  2008cited by this paper
• Rescuing proteins of low kinetic stability by chaperones and natural ligands phenylketonuria, a case study.

  2008cited by this paper
• Cellular mechanisms of tumour suppression by the retinoblastoma gene

  2008cited by this paper

• Beneficial Handling of Molecular Chaperones (Chaperonotherapy) in Glioblastoma and Neuroblastoma: Novel Therapeutic Targets or Potential Agents?

  2025cites this paper
• Structural dynamics and functional cooperativity of human NQO1 by ambient temperature serial crystallography and simulations

  2023cites this paper
• Skullcapflavone II, a novel NQO1 inhibitor, alleviates aristolochic acid I-induced liver and kidney injury in mice

  2023cites this paper
• Novel insights into RB1 mutation.

  2022cites this paper
• A single evolutionarily divergent mutation determines the different FAD‐binding affinities of human and rat NQO1 due to site‐specific phosphorylation

  2021cites this paper
• Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations

  2020cites this paper
• Naturally-Occurring Rare Mutations Cause Mild to Catastrophic Effects in the Multifunctional and Cancer-Associated NQO1 Protein

  2020cites this paper
• Cancer-associated variants of human NQO1: impacts on inhibitor binding and cooperativity

  2019cites this paper
• A Dynamic Core in Human NQO1 Controls the Functional and Stability Effects of Ligand Binding and Their Communication across the Enzyme Dimer

  2019cites this paper
• Functional and Stability Effects of Ligand Binding

  2019cites this paper
• Phosphorylation compromises FAD binding and intracellular stability of wild-type and cancer-associated NQO1: Insights into flavo-proteome stability.

  2019cites this paper
• NQO1: A target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms.

  2019cites this paper
• Anion-specific interaction with human NQO1 inhibits flavin binding.

  2019cites this paper
• NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places

  2018cites this paper